Josephine B. Walton
Oncology R&D
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
MYC deregulation sensitizes cancer cells to N-myristoyltransferase inhibition.
Journal: Cell reports
Published: June 25, 2025
PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma.
Journal: Cancer research
Published: December 08, 2023
Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.
Journal: Journal for immunotherapy of cancer
Published: February 21, 2022
Optimization of an Imidazo[1,2-a]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with In Vivo Efficacy.
Journal: Journal of medicinal chemistry
Published: September 03, 2021
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
Journal: Cell reports
Published: May 28, 2020
Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery.
Journal: Journal for immunotherapy of cancer
Published: May 27, 2019
Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses.
Journal: Cell reports
Published: February 21, 2019
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.
Journal: Cancer
Published: August 24, 2018
Author Correction: CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.
Journal: Scientific reports
Published: April 14, 2018
CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.
Journal: Scientific reports
Published: September 11, 2017
Last Updated: 09/26/2026